Hepatitis C virus (HCV) infection is a prevalent infection in most developed countries
affecting 1.5–2% of the general population [1]. The natural history of this infection has been …

Since liver transplantation was approved for the treatment of end stage liver disease,
calcineurin inhibitors (CNI′ s) have played a critical role in the preservation of allograft …

The first human orthotopic liver transplantation (LT) in Europe was performed by Sir Roy
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …

In the last few decades liver transplantation (LTx) has become a reliable life-saving
procedure for patients with chronic end-stage liver diseases. LTx has an outstanding …

Recurrence of hepatitis C after liver transplantation represents the most important clinical
problem facing liver transplant physicians and surgeons. Moreover, I believe it now is well …

1. Approximately 10% to 25% of hepatitis C virus–infected recipients of liver allografts will
develop cirrhosis within 5 years of transplantation; this acceleration of the natural history of …

Hepatitis C virus (HCV)‐related end‐stage liver disease is the main indication for liver
transplantation performed in Europe and the United States. Recurrence of hepatitis C in the …

HCV related liver disease is the most common indication for liver transplantation.
Recurrence of HCV infection is universal and has a substantial impact on patient and graft …

A prospective evaluation was performed to study the potential benefits of the use of
interleukin‐2 receptor antibody (IL‐2Rab) in the induction therapy with early elimination of …

Over the last two decades there has been a significant increase in the number and types of
immunosuppressive agents that have been available to clinicians. The protocols for …